The U.S. Food and Drug Administration (FDA) has approved new medications for chronic weight management in adults with obesity or overweight. Two of these medications are Zepbound (tirzepatide) injection and Wegovy (semaglutide) injection. Zepbound is approved for adults with obesity or overweight with at least one weight-related condition, while Wegovy is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater
. The FDA warns consumers to avoid certain male enhancement and weight loss products that have been found to contain hidden ingredients. The agency found that nearly 50 male enhancement or weight loss products contained undeclared active pharmaceutical ingredients, including sildenafil, tadalafil, vardenafil, sibutramine, desmethylsibutramine, phenolphthalein, and/or fluoxetine. The FDA's tainted products database can help consumers identify potentially dangerous products, and the agency urges caution when using products promoted for sexual enhancement, weight loss, bodybuilding, sleep aids, or pain relief
. The FDA is responsible for enforcing the laws and regulations governing dietary supplements. The agency conducts inspections, monitors the marketplace, examines dietary supplements and dietary ingredients offered for import, and reviews notifications for dietary supplements. Manufacturers or distributors must notify the FDA in advance and submit safety information if they intend to market a dietary supplement in the United States that contains a "new dietary ingredient." Dietary supplement labels are required to bear a product name and a statement that it is a "dietary supplement" or equivalent term, the name and place of the manufacturer, packer, or distributor, and the net quantity of contents
